Rizafilm
NDC Package 35781-0605-8
Package Information
Rizafilm (rizatriptan benzoate) films is rizaFilm™ is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age.Limitations of UseRizaFilm should only be used where a clear diagnosis of migraine has been established. This formulation utilizes a film delivery system. Marketed by Gensco Laboratories Llc, this product is identified by NDC 35781-0605 and is authorized under FDA application NDA205394.
Identification & Billing
- RxCUI: 2634482 - rizatriptan 10 MG Oral Film
- RxCUI: 2634482 - rizatriptan 10 MG (as rizatriptan benzoate 14.53 MG) Oral Film
- RxCUI: 2634489 - rizatriptan 5 MG Oral Film
- RxCUI: 2634489 - rizatriptan 5 MG (as rizatriptan benzoate 7.265 MG) Oral Film
- RxCUI: 2672955 - RizaFilm 10 MG Oral Film
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 35781 - Gensco Laboratories Llc
- 35781-0605 - Rizafilm
- 35781-0605-8 - 18 POUCH in 1 CARTON / 1 FILM in 1 POUCH (35781-0605-1)
- 35781-0605 - Rizafilm
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 35781-0605-8 identifies a specific commercial package of 18 pouch in 1 carton / 1 film in 1 pouch (35781-0605-1) of Rizafilm, a human prescription drug labeled by Gensco Laboratories Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 18 billable units per package. This film is formulated for oral use and contains rizatriptan benzoate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gensco Laboratories Llc on April 27, 2026. The current certification is valid through December 31, 2026.
How is this Gensco Laboratories Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 35781060508. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 18 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.